Literature DB >> 23523631

cAMP signalling decreases p300 protein levels by promoting its ubiquitin/proteasome dependent degradation via Epac and p38 MAPK in lung cancer cells.

Min-Jae Jeong1, Eui-Jun Kim, Eun-Ah Cho, Sang-Kyu Ye, Gyeong Hoon Kang, Yong-Sung Juhnn.   

Abstract

The transcriptional coactivator p300 functions as a histone acetyltransferase and a scaffold for transcription factors. We investigated the effect of cAMP signalling on p300 expression. The activation of cAMP signalling by the expression of constitutively active Gαs or by treatment with isoproterenol decreased the p300 protein expression in lung cancer cells. Isoproterenol promoted the ubiquitination and subsequent proteasomal degradation of p300 in an Epac-dependent manner. Epac promoted p300 degradation by inhibiting the activity of p38 MAPK. It is concluded that cAMP signalling decreases the level of the p300 protein by promoting its ubiquitin-proteasome dependent degradation, which is mediated by Epac and p38 MAPK, in lung cancer cells.
Copyright © 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23523631     DOI: 10.1016/j.febslet.2013.03.010

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  9 in total

1.  C6orf106 is a novel inhibitor of the interferon-regulatory factor 3-dependent innate antiviral response.

Authors:  Rebecca L Ambrose; Yu Chih Liu; Timothy E Adams; Andrew G D Bean; Cameron R Stewart
Journal:  J Biol Chem       Date:  2018-05-25       Impact factor: 5.157

2.  p300/Sp1-Mediated High Expression of p16 Promotes Endothelial Progenitor Cell Senescence Leading to the Occurrence of Chronic Obstructive Pulmonary Disease.

Authors:  Zhihui He; Huaihuai Peng; Min Gao; Guibin Liang; Menghao Zeng; Xuefeng Zhang
Journal:  Mediators Inflamm       Date:  2021-08-19       Impact factor: 4.711

Review 3.  Insights into exchange factor directly activated by cAMP (EPAC) as potential target for cancer treatment.

Authors:  Naveen Kumar; Peeyush Prasad; Eshna Jash; Megha Saini; Amjad Husain; Aaron Goldman; Seema Sehrawat
Journal:  Mol Cell Biochem       Date:  2018-02-07       Impact factor: 3.396

4.  The suppressive role of miR-542-5p in NSCLC: the evidence from clinical data and in vivo validation using a chick chorioallantoic membrane model.

Authors:  Rong-Quan He; Xiao-Jiao Li; Lu Liang; You Xie; Dian-Zhong Luo; Jie Ma; Zhi-Gang Peng; Xiao-Hua Hu; Gang Chen
Journal:  BMC Cancer       Date:  2017-09-19       Impact factor: 4.430

5.  Ubiquitylation of MFHAS1 by the ubiquitin ligase praja2 promotes M1 macrophage polarization by activating JNK and p38 pathways.

Authors:  Jing Zhong; Huihui Wang; Wankun Chen; Zhirong Sun; Jiawei Chen; Yajun Xu; Meilin Weng; Qiqing Shi; Duan Ma; Changhong Miao
Journal:  Cell Death Dis       Date:  2017-05-04       Impact factor: 8.469

Review 6.  The Role of Neuropeptide-Stimulated cAMP-EPACs Signalling in Cancer Cells.

Authors:  Zhengyin Gao; Weng I Lei; Leo Tsz On Lee
Journal:  Molecules       Date:  2022-01-05       Impact factor: 4.411

7.  Transcriptome analysis of porcine PBMCs reveals lipopolysaccharide-induced immunomodulatory responses and crosstalk of immune and glucocorticoid receptor signaling.

Authors:  Zhiwei Li; Nares Trakooljul; Frieder Hadlich; Siriluck Ponsuksili; Klaus Wimmers; Eduard Murani
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

Review 8.  A dynamic interface between ubiquitylation and cAMP signaling.

Authors:  Laura Rinaldi; Maria Sepe; Rossella Delle Donne; Antonio Feliciello
Journal:  Front Pharmacol       Date:  2015-09-04       Impact factor: 5.810

9.  Endothelin-1/endothelin A receptor-mediated biased signaling is a new player in modulating human ovarian cancer cell tumorigenesis.

Authors:  Jian-peng Teoh; Kyoung-mi Park; Yongchao Wang; Qiuping Hu; Sangmi Kim; Guangyu Wu; Shuang Huang; Nita Maihle; Il-man Kim
Journal:  Cell Signal       Date:  2014-09-03       Impact factor: 4.315

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.